| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01675050 Details | 2017-08-30 Interventional | 2 | 4 | Cyproheptadine Abdominal Pain Functional Abdo… | Due to the wide availability of the drug in clinical practice, it was impossible to recruit
adequate numbers for scientific power. Statistical analyses were not conducted due to small sample size. Results should be interpreted with extreme caution. | |||
| NCT01565148 Details | 2017-08-30 Interventional | 2 | 185 | Ranibizumab Edema Macular Edema Diabetic Macula… | Patient's disease progressed and Vision Dropped which led to exit from the study - | |||
| NCT01170364 Details | 2017-08-30 Interventional | 4 | 14 | Sibutramine Obesity | Terminated due to sibutramine being withdrawn from the market. Early termination of the study given the withdrawal of sibutramine from the US market. | |||
| NCT02421029 Details | 2017-08-29 Interventional | 4 | 0 | Calcium Calcium, Dietar… Edetic Acid Pentetic Acid Heavy Metal Poi… Heavy Metal Tox… | it was logistically difficult to obtain the drug needed to conduct the study - | |||
| NCT02212210 Details | 2017-08-29 Interventional | 1 | 135 | Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Labor Pain Complication of… Fever | PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study is
closed - | |||
| NCT01386255 Details | 2017-08-29 Interventional | 4 | 0 | Baclofen Cerebral Palsy GERD | No participants were enrolled - | |||
| NCT01502761 Details | 2017-08-28 Interventional | 1/2 | 4 | Magnesium Sulfa… Stroke Acute Stroke | No safety issues. Low enrollment secondary to negative stroke studies 2013 The trial was terminated early (with enrollment only in the first arm) by the investigators due to low enrollment (given results of relevant studies at the time) . There were no safety concerns with the trial or the agent. | |||
| NCT01375374 2010-022534-84 Details | 2017-08-28 Interventional | 3 | 11 | Lacosamide Levetiracetam Epilepsies, Par… Epilepsy, Parti… | Slow progress despite recruitment boosting efforts e.g., expert advice obtained from leading
study center Investigators; decision thus made to terminate. The results of this study are limited due to the small sample size. | |||
| NCT00803309 Details | 2017-08-28 Interventional | 4 | [1 Refs] | 99 | Interferon alph… Interferon-alph… Interferons Peginterferon a… Ribavirin Hepatitis Hepatitis C Hepatitis C, Ch… | At the end of the planned recruitment period the expected number of subjects could not be
included in the trial. - | ||
| NCT00485472 2006-005048-97 Details | 2017-08-28 Interventional | 2 | 194 | Lacosamide Osteoarthritis Osteoarthritis,… | Based on the outcome of the planned first interim analysis, it was decided not to continue the
trial. No safety concerns were identified. - | |||
| NCT03013387 Details | 2017-08-25 Interventional | 2 | 0 | Edotreotide Octreotide Medulloblastoma Meningioma Neuroblastoma Neuroendrocrine… | This project has undergone a significant amount of updates and has been resubmitted under IRB#
201708778 - | |||
| NCT00089414 Details | 2017-08-25 Interventional | 2 | 5 | Drospirenone Drospirenone an… Estradiol Ethinyl Estradi… Progesterone Depression Premenstrual Dy… Premenstrual Sy… PMDD PMS | Informed by manufacturer that CDB-2914 crosses blood-brain barrier invalidating Arm #3 of
protocol. Protocol terminated after receiving information from manufacturer (Pharma) that CDB-2914 crosses the blood-brain barrier, invalidating Arm #3 due to potential CNS effect of the compound on behavior. | |||
| NCT03191981 Details | 2017-08-24 Interventional | 1/2 | 0 | Cyclophosphamid… Lenalidomide Pembrolizumab Multiple Myelom… Neoplasms, Plas… Myeloma Multipl… | Withdrawal of pharma support prior to opening to recruitment - | |||
| NCT02345746 Details | 2017-08-24 Interventional | 2 | 0 | Fluorouracil Folic Acid Leucovorin Levoleucovorin Oxaliplatin Colorectal Neop… Metastatic Colo… | patient population - | |||
| NCT02049151 2013-003760-30 Details | 2017-08-23 Interventional | 3 | 35 | Cyclophosphamid… Carcinoma, Non-… | The study is terminated prematurely as the sponsor decided to discontinue program with
Tecemotide in NSCLC Sponsor discontinued development of tecemotide (L-BLP25) in NSCLC, hence the study was terminated. | |||
| NCT01668017 Details | 2017-08-23 Interventional | 1 | 26 | Niacinamide Carcinoma, Hepa… Advanced Solid … Hepatocellular … | The sponsor decided not to conduct the expansion part of trial (part 2) Due to the Sponsor's decision not to pursue the study drug as monotherapy, the Expansion Phase (Part 2) of the study was not conducted. | |||
| NCT01508104 Details | 2017-08-23 Interventional | 1 | 19 | Dactolisib Everolimus Cancer | funding - | |||
| NCT02902744 Details | 2017-08-22 Interventional | 4 | 0 | Fluocinolone Ac… Edema Macular Edema Diabetic Macula… | The study was withdrawn due to difficult recruitment of patients for the study; No participants
were enrolled in the study. - | |||
| NCT02810886 Details | 2017-08-22 Interventional | 2 | 0 | Gallium 68 PSMA… Prostatic Neopl… Recurrence Prostate Cancer… | Recent publications demonstrating the clinical interest in performing 68Ga-PSMA for recurrence
detection of prostate cancer patients with biochemical relapse - | |||
| NCT01662115 Details | 2017-08-22 Interventional | 4 | 4 | Nicotine Ileus Post-operative … | Study has been terminated due linability to recruit the targeted participants. Aimed for 300
participants and only 4 were enrolled after 1 year. Principal Investigator decided for an early termination of the enrollment period due to small numbers of subjects consented, with limited data to make conclusions. |